Background
Phase III, double-blind, placebo-controlled RCT. 460 patients with NDMM who achieved at least stable disease after single ASCT (high-dose melphalan 200mg/m²). Randomized at day +100 post-ASCT to lenalidomide maintenance vs placebo. Lenalidomide's immunomodulatory and anti-myeloma properties were hypothesized to maintain remission depth and extend PFS and OS.
Interventions and follow up
Arm A: Lenalidomide 10mg PO days 1–28 q28d (escalation to 15mg if tolerated after 3 months), until progression or unacceptable toxicity; started day +100 post-ASCT
Arm B: Matching placebo PO daily, started day +100 post-ASCT; crossover to open-label lenalidomide allowed at progression
Primary endpoint: Time to progression (TTP)
Median follow up: 34 months (primary); 91 months (long-term)
Arm B: Matching placebo PO daily, started day +100 post-ASCT; crossover to open-label lenalidomide allowed at progression
Primary endpoint: Time to progression (TTP)
Median follow up: 34 months (primary); 91 months (long-term)
Results
Median TTP (primary): 46.0 months (lenalidomide) vs 27.0 months (placebo) — HR 0.48, P<.001
4-year OS (primary): 88% vs 80% — HR 0.61, P=.028
Long-term mOS (JCO 2017, 91-mo follow-up): Not reached vs 86.1 months — HR 0.61, P=.0009
MRD conversion: Higher in lenalidomide arm (exploratory)
4-year OS (primary): 88% vs 80% — HR 0.61, P=.028
Long-term mOS (JCO 2017, 91-mo follow-up): Not reached vs 86.1 months — HR 0.61, P=.0009
MRD conversion: Higher in lenalidomide arm (exploratory)
Adverse events
Hematologic (grade ≥3): Neutropenia 36% (lenalidomide) vs 6% (placebo); thrombocytopenia 10% vs 3%
Infection/constitutional (grade ≥3): Infections 16% vs 11%; fatigue 15%
Second primary malignancies: 7.8% (lenalidomide) vs 2.6% (placebo) over 6 years — predominantly hematologic (AML/MDS) and solid tumors
Infection/constitutional (grade ≥3): Infections 16% vs 11%; fatigue 15%
Second primary malignancies: 7.8% (lenalidomide) vs 2.6% (placebo) over 6 years — predominantly hematologic (AML/MDS) and solid tumors
Conclusions
Lenalidomide maintenance post-ASCT significantly improved TTP and OS in NDMM, with a long-term OS benefit of ~1 year. The SPM risk (~7.8%) requires informed-consent discussion but is outweighed by the OS benefit in most patients. Established lenalidomide maintenance as standard of care post-ASCT in NDMM.
Key Limitations
SPM signal (AML/MDS) is real — cumulative incidence 7.8% at 6 years, predominantly in patients with prior alkylator exposure. Crossover at progression complicates OS interpretation (likely underestimating lenalidomide's true benefit). Pre-novel-induction-agent era (VRd, Dara-VRd) may affect magnitude of benefit. Optimal maintenance duration remains undefined.
Clinical Context
CALGB 100104 with IFM 2005-02 established lenalidomide post-ASCT maintenance as global standard; FDA approved lenalidomide maintenance January 2017; ESMO endorses it. Current evolution: AURIGA (daratumumab + lenalidomide maintenance) and MIDAS (MRD-guided maintenance discontinuation) are refining whether MRD-negative patients need indefinite maintenance.